Lusduna Nexvue FDA Approval Status
FDA Approved: No
Brand name: Lusduna Nexvue
Generic name: insulin glargine
Previous Name: MK-1293
Company: Merck
Treatment for: Diabetes, Type 1, Type 2 Diabetes
Lusduna Nexvue (insulin glargine injection) is a follow-on insulin product (referenced to Lantus) in development for the treatment of patients with type 1 and type 2 diabetes.
Development timeline for Lusduna Nexvue
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.